Trials / Completed
CompletedNCT00324116
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium (Macugen) | 0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2006-05-10
- Last updated
- 2010-03-23
- Results posted
- 2009-10-02
Locations
34 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00324116. Inclusion in this directory is not an endorsement.